Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 21, 2020

BMS reports positive data of Opdivo in renal cell carcinoma trial

Bristol Myers Squibb (BMS) and Exelixis have reported that an Opdivo (nivolumab) and Cabometyx (cabozantinib) combination showed significant improvements across all efficacy endpoints in the Phase III CheckMate -9ER trial for advanced renal cell carcinoma (RCC).

Bristol Myers Squibb (BMS) and Exelixis have reported that an Opdivo (nivolumab) and Cabometyx (cabozantinib) combination showed significant improvements across all efficacy endpoints in the Phase III CheckMate -9ER trial for advanced renal cell carcinoma (RCC).

CheckMate -9ER is an open-label, randomised, multi-national trial involving 651 patients.

The primary endpoint was progression-free survival (PFS), while secondary endpoints included overall survival (OS) and objective response rate (ORR).

Statistics show that more than 140,000 people die per year due to RCC globally, making it the most common type of kidney cancer in adults.

The study showed that Opdivo plus Cabometyx reduced the risk of death by 40% when compared to sunitinib in previously untreated advanced RCC patients.

Patients administered with the combination demonstrated double median PFS against those on sunitinib at 16.6 months and 8.3 months, respectively.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Furthermore, the combination showed a superior ORR with 56% of the participants responding to the combination versus to 27% of those in sunitinib group.

In addition, 8% on the combination therapy achieved a complete response compared to 5% under the sunitinib arm.

Data showed that the combination therapy led to a longer duration of response than sunitinib, with a median duration of 20.2 months versus 11.5 months, respectively.

Across the pre-specified International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk and PD-L1 subgroups, consistency was observed in all the key efficacy data.

The results also showed that the combination was well tolerated. The incidence of treatment-related adverse events (TRAEs) was found to be slightly higher in the combination arm than in the sunitinib group.

Bristol Myers Squibb Oncology Development vice-president and interim head Nick Botwood said: “With the promising results from CheckMate -9ER, we hope to bring the highly efficacious combination of Opdivo and Cabometyx to patients with advanced renal cell carcinoma for whom an immunotherapy plus tyrosine kinase inhibitor regimen is chosen.”

The trial is sponsored by BMS and Ono Pharmaceutical, while Exelixis, Ipsen and Takeda Pharmaceutical jointly funded the study.

Last month, BMS reported positive data from the Phase III CheckMate -743 trial of Opdivo plus Yervoy in previously untreated, unresectable malignant pleural mesothelioma (MPM).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU